세계의 뇌척수염 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Encephalomyelitis Market is presumed to reach the market size of nearly USD 34.88 BN by 2030 from USD 21.28 BN in 2022 with a CAGR of 6.37% under the study period 2023 - 2030.

Encephalomyelitis refers to the inflammation of both the brain (encephalo) and the spinal cord (myelitis). This may be caused due to infections, autoimmune disorders, and other inflammatory processes. This condition can be acute, meaning it occurs suddenly with severe symptoms, or it can be chronic, involving long-term or recurrent inflammation.

MARKET DYNAMICS

The factors driving progress and developments in the understanding and management of encephalomyelitis include ongoing research advances in neurology and immunology. These efforts contribute to improved diagnostic tools and treatment options. Increased awareness initiatives focused on various forms of encephalomyelitis, such as ADEM or ME/CFS, play a vital role in promoting early diagnosis and intervention. Technological innovations in medical imaging and diagnostic tools further enhance the ability to accurately diagnose and monitor encephalomyelitis, shaping the direction of research and clinical practices. Collaborative efforts among healthcare professionals, researchers, patient advocacy groups, and pharmaceutical companies facilitate the exchange of knowledge and resources, fostering progress in the field. The discovery and development of new treatments or therapeutic approaches for encephalomyelitis contribute to increased interest and investment in the medical and pharmaceutical sectors, promoting advancements in managing this complex medical condition.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of encephalomyelitis. The growth and trends of encephalomyelitis industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the encephalomyelitis market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By End-Users

• Clinics
• Hospitals
• Others

By Treatment

• Surgery
• Plasmapheresis
• Drug Treatment
• Others

By Type

• Equine Encephalomyelitis
• Associated Encephalomyelitis
• AntiMOG
• Encephalomyelitis Disseminata
• Acute Disseminated Encephalomyelitis
• AIDS-Related Encephalomyelitis
• Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Encephalomyelitis market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Encephalomyelitis market include Oncomed Pharmaceuticals, Pfizer Inc., Immunomedics, Takeda Pharmaceuticals, AbbVie Inc., Janssen Biotech, Inc., AstraZeneca Plc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Novartis AG, Bayer AG, Merck & Co. Inc., Amgen Inc., Spectrum Pharmaceuticals Inc., GlaxoSmithKline Plc., Sanofi, and Bristol-Myers Squibb Company. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . ENCEPHALOMYELITIS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By End-Users
  • 3.7.2 Market Attractiveness Analysis By Treatment
  • 3.7.3 Market Attractiveness Analysis By Type
  • 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL ENCEPHALOMYELITIS MARKET ANALYSIS BY END-USERS

• 5.1 Overview by End-Users
• 5.2 Historical and Forecast Data
• 5.3 Analysis by End-Users
• 5.4 Clinics Historic and Forecast Sales by Regions
• 5.5 Hospitals Historic and Forecast Sales by Regions
• 5.6 Others Historic and Forecast Sales by Regions

6 . GLOBAL ENCEPHALOMYELITIS MARKET ANALYSIS BY TREATMENT

• 6.1 Overview by Treatment
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Treatment
• 6.4 Surgery Historic and Forecast Sales by Regions
• 6.5 Plasmapheresis Historic and Forecast Sales by Regions
• 6.6 Drug Treatment Historic and Forecast Sales by Regions
• 6.7 Others Historic and Forecast Sales by Regions

7 . GLOBAL ENCEPHALOMYELITIS MARKET ANALYSIS BY TYPE

• 7.1 Overview by Type
• 7.2 Historical and Forecast Data
• 7.3 Analysis by Type
• 7.4 Equine Encephalomyelitis Historic and Forecast Sales by Regions
• 7.5 Associated Encephalomyelitis Historic and Forecast Sales by Regions
• 7.6 AntiMOG Historic and Forecast Sales by Regions
• 7.7 Encephalomyelitis Disseminata Historic and Forecast Sales by Regions
• 7.8 Acute Disseminated Encephalomyelitis Historic and Forecast Sales by Regions
• 7.9 AIDS-Related Encephalomyelitis Historic and Forecast Sales by Regions
• 7.10. Others Historic and Forecast Sales by Regions

8 . GLOBAL ENCEPHALOMYELITIS MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2. North America By Segment Sales Analysis
  • 8.3.3. North America By Country Sales Analysis
  • 8.3.4. United State Sales Analysis
  • 8.3.5. Canada Sales Analysis
  • 8.3.6. Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2. Europe by Segment Sales Analysis
  • 8.4.3. Europe by Country Sales Analysis
  • 8.4.4. United Kingdom Sales Analysis
  • 8.4.5. France Sales Analysis
  • 8.4.6. Germany Sales Analysis
  • 8.4.7. Italy Sales Analysis
  • 8.4.8. Russia Sales Analysis
  • 8.4.9. Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2. Asia Pacific by Segment Sales Analysis
  • 8.5.3. Asia Pacific by Country Sales Analysis
  • 8.5.4. China Sales Analysis
  • 8.5.5. India Sales Analysis
  • 8.5.6. Japan Sales Analysis
  • 8.5.7. South Korea Sales Analysis
  • 8.5.8. Australia Sales Analysis
  • 8.5.9. South East Asia Sales Analysis
  • 8.5.10. Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2. Latin America by Segment Sales Analysis
  • 8.6.3. Latin America by Country Sales Analysis
  • 8.6.4. Brazil Sales Analysis
  • 8.6.5. Argentina Sales Analysis
  • 8.6.6. Peru Sales Analysis
  • 8.6.7. Chile Sales Analysis
  • 8.6.8. Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2. Middle East & Africa by Segment Sales Analysis
  • 8.7.3. Middle East & Africa by Country Sales Analysis
  • 8.7.4. Saudi Arabia Sales Analysis
  • 8.7.5. UAE Sales Analysis
  • 8.7.6. Israel Sales Analysis
  • 8.7.7. South Africa Sales Analysis
  • 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE ENCEPHALOMYELITIS COMPANIES

• 9.1. Encephalomyelitis Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10 . COMPANY PROFILES OF ENCEPHALOMYELITIS INDUSTRY

• 10.1. Company Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Oncomed Pharmaceuticals
  • 10.3.1. Company Overview
  • 10.3.2. Company Revenue
  • 10.3.3. Products
  • 10.3.4. Recent Developments
• 10.4. Pfizer Inc.
  • 10.4.1. Company Overview
  • 10.4.2. Company Revenue
  • 10.4.3. Products
  • 10.4.4. Recent Developments
• 10.5. Immunomedics
  • 10.5.1. Company Overview
  • 10.5.2. Company Revenue
  • 10.5.3. Products
  • 10.5.4. Recent Developments
• 10.6. Takeda Pharmaceuticals
  • 10.6.1. Company Overview
  • 10.6.2. Company Revenue
  • 10.6.3. Products
  • 10.6.4. Recent Developments
• 10.7. AbbVie Inc.
  • 10.7.1. Company Overview
  • 10.7.2. Company Revenue
  • 10.7.3. Products
  • 10.7.4. Recent Developments
• 10.8. Janssen Biotech Inc.
  • 10.8.1. Company Overview
  • 10.8.2. Company Revenue
  • 10.8.3. Products
  • 10.8.4. Recent Developments
• 10.9. AstraZeneca Plc.
  • 10.9.1. Company Overview
  • 10.9.2. Company Revenue
  • 10.9.3. Products
  • 10.9.4. Recent Developments
• 10.10. Eli Lilly and Company
  • 10.10.1. Company Overview
  • 10.10.2. Company Revenue
  • 10.10.3. Products
  • 10.10.4. Recent Developments
• 10.11. F. Hoffmann-La Roche Ltd.
  • 10.11.1. Company Overview
  • 10.11.2. Company Revenue
  • 10.11.3. Products
  • 10.11.4. Recent Developments
• 10.12. Novartis AG
  • 10.12.1. Company Overview
  • 10.12.2. Company Revenue
  • 10.12.3. Products
  • 10.12.4. Recent Developments
• 10.13. Bayer AG
  • 10.13.1. Company Overview
  • 10.13.2. Company Revenue
  • 10.13.3. Products
  • 10.13.4. Recent Developments
• 10.14. Merck & Co. Inc.
  • 10.14.1. Company Overview
  • 10.14.2. Company Revenue
  • 10.14.3. Products
  • 10.14.4. Recent Developments
• 10.15. Amgen Inc.
  • 10.15.1. Company Overview
  • 10.15.2. Company Revenue
  • 10.15.3. Products
  • 10.15.4. Recent Developments
• 10.16. Spectrum Pharmaceuticals Inc.
  • 10.16.1. Company Overview
  • 10.16.2. Company Revenue
  • 10.16.3. Products
  • 10.16.4. Recent Developments
• 10.17. GlaxoSmithKline Plc.
  • 10.17.1. Company Overview
  • 10.17.2. Company Revenue
  • 10.17.3. Products
  • 10.17.4. Recent Developments
• 10.18. Sanofi
  • 10.18.1. Company Overview
  • 10.18.2. Company Revenue
  • 10.18.3. Products
  • 10.18.4. Recent Developments
• 10.19. Bristol-Myers Squibb Company
  • 10.19.1. Company Overview
  • 10.19.2. Company Revenue
  • 10.19.3. Products
  • 10.19.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies